Pasithea, Evotec Ink Drug Development Pact

by Vandana Singh, Benzinga Editor

October 11, 2021 8:34 AM | 24 seconds read |

Pasithea Therapeutics Corp KTTA has initiated a new chemical entity development program and named Evotec SE EVOTF its research partner.
No deal terms were disclosed.
Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia," stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
Price Action: KTTA shares closed 1.50% lower at $2.62 on Friday.

Posted In: Biotech News Penny Stocks Health Care Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.